These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 1970283)
1. Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. Munger MA; Rutherford WF; Anderson L; Hakki AI; Gonzalez FM; Bednarczyk EM; Emmanuel G; Weed SG; Panacek EA; Green JA Crit Care Med; 1990 May; 18(5):502-4. PubMed ID: 1970283 [TBL] [Abstract][Full Text] [Related]
2. Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension. Pilmer BL; Green JA; Panacek EA; Elliot WJ; Murphy MB; Rutherford W; Nara AR J Clin Pharmacol; 1993 Jun; 33(6):549-53. PubMed ID: 8103527 [TBL] [Abstract][Full Text] [Related]
3. Comparative effects of fenoldopam mesylate and nitroprusside on left ventricular performance in severe systemic hypertension. Hackman BB; Griffin B; Mills M; Ramanathan KB Am J Cardiol; 1992 Apr; 69(9):918-22. PubMed ID: 1347965 [TBL] [Abstract][Full Text] [Related]
4. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Shusterman NH; Elliott WJ; White WB Am J Med; 1993 Aug; 95(2):161-8. PubMed ID: 8102835 [TBL] [Abstract][Full Text] [Related]
5. Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Reisin E; Huth MM; Nguyen BP; Weed SG; Gonzalez FM Hypertension; 1990 Feb; 15(2 Suppl):I59-62. PubMed ID: 1967592 [TBL] [Abstract][Full Text] [Related]
6. Effects of intravenous fenoldopam (SK&F 82526-J) on blood pressure in severe hypertension. SK&F Fenoldopam Working Group. Cardiovasc Drugs Ther; 1992 Aug; 6(4):445-6. PubMed ID: 1355665 [No Abstract] [Full Text] [Related]
7. Fenoldopam infusion for the treatment of postoperative hypertension. Goldberg ME; Cantillo J; Nemiroff MS; Subramoni J; Muñoz R; Torjman M; Schieren H J Clin Anesth; 1993; 5(5):386-91. PubMed ID: 8105829 [TBL] [Abstract][Full Text] [Related]
8. Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure. Munger MA; Benotti JR; Green JA; Jarvis RC; Nara AR; McCue JE; Pospisil RA; Kasmer RJ Am J Cardiol; 1990 Jan; 65(3):206-10. PubMed ID: 1967511 [TBL] [Abstract][Full Text] [Related]
9. The effect of fenoldopam on renal haemodynamics and natriuresis in chronic renal failure. de Fijter CW; Comans EF; de Vries PM; Oe PL; Roos JC; Smit AJ; Streurman O; Donker AJ Neth J Med; 1990 Jun; 36(5-6):267-78. PubMed ID: 1975651 [TBL] [Abstract][Full Text] [Related]
10. Intravenous fenoldopam infusion in severe heart failure. Patel JJ; Mitha AS; Sareli P; de Vaal JB Cardiovasc Drugs Ther; 1993 Feb; 7(1):97-101. PubMed ID: 8097927 [TBL] [Abstract][Full Text] [Related]
11. Electrocardiographic changes during acute treatment of hypertensive emergencies with sodium nitroprusside or fenoldopam. Gretler DD; Elliott WJ; Moscucci M; Childers RW; Murphy MB Arch Intern Med; 1992 Dec; 152(12):2445-8. PubMed ID: 1360793 [TBL] [Abstract][Full Text] [Related]
12. Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. White WB; Radford MJ; Gonzalez FM; Weed SG; McCabe EJ; Katz AM J Am Coll Cardiol; 1988 May; 11(5):1118-23. PubMed ID: 2895780 [TBL] [Abstract][Full Text] [Related]
13. Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans. Elliott WJ; Karnezis TA; Silverman RA; Geanon J; Tripathi RC; Murphy MB Clin Pharmacol Ther; 1991 Mar; 49(3):285-93. PubMed ID: 1672512 [TBL] [Abstract][Full Text] [Related]
14. Hemodynamic profile of intravenous fenoldopam in patients with hypertensive crisis. Bodmann KF; Tröster S; Clemens R; Schuster HP Clin Investig; 1993 Dec; 72(1):60-4. PubMed ID: 7907900 [TBL] [Abstract][Full Text] [Related]
15. Evidence against a role for dopamine D1 receptors in the myocardium of the pig. Van Woerkens LJ; Duncker DJ; Den Boer MO; McFalls EO; Sassen LM; Saxena PR; Verdouw PD Br J Pharmacol; 1991 Sep; 104(1):246-50. PubMed ID: 1686206 [TBL] [Abstract][Full Text] [Related]
16. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Elliott WJ; Weber RR; Nelson KS; Oliner CM; Fumo MT; Gretler DD; McCray GR; Murphy MB Circulation; 1990 Mar; 81(3):970-7. PubMed ID: 1968368 [TBL] [Abstract][Full Text] [Related]
17. Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects. Bughi S; Horton R; Antonipillai I; Manoogian C; Ehrlich L; Nadler J J Clin Endocrinol Metab; 1989 Dec; 69(6):1116-21. PubMed ID: 2573613 [TBL] [Abstract][Full Text] [Related]
18. Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group. Panacek EA; Bednarczyk EM; Dunbar LM; Foulke GE; Holcslaw TL Acad Emerg Med; 1995 Nov; 2(11):959-65. PubMed ID: 8536121 [TBL] [Abstract][Full Text] [Related]
19. Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects. Taylor AA; Shepherd AM; Polvino W; Mangoo-Karim R; Ballard K; Sunthornyothin S; Luther RR; Pool JL Am J Hypertens; 1999 Sep; 12(9 Pt 1):906-14. PubMed ID: 10509549 [TBL] [Abstract][Full Text] [Related]
20. Cardiovascular and renal profile of acute peripheral dopamine1-receptor agonism with fenoldopam. Glück Z; Jossen L; Weidmann P; Gnädinger MP; Peheim E Hypertension; 1987 Jul; 10(1):43-54. PubMed ID: 2885268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]